In this exclusive interview, Fintan Walton, CEO of PharmaVentures, speaks with Marc Funk, the new CEO of Recipharm.
Recipharm is a leading Swedish CDMO, founded in 1995, which has expanded to over 30 sites across 10 countries which are mainly in Europe, but also in Israel, India, and North America. The company’s successful inorganic growth has been largely through the build and buy model of its founders, according to Marc.
They discuss the company’s current situation and how Marc plans to take it forward, including:
The takeover of Recipharm by EQT, a global investment organisation with a “passion for future-proofing companies”
Focus on operational excellence, meeting the needs unmet by the competition, emerging technologies, and innovation
Opportunities in the areas of small molecules, biologics, and North America
Recipharm’s and EQT’s “priority 1” – customer focus
Affordable and safe drugs
How Recipharm are operating during the COVID-19 pandemic
What Marc sees as his biggest challenges, both now and in the future
Watch: Contract Manufacturing in the Pharmaceutical Industry: Recipharm
Can Partnering Conference Cancellations Affect Dealmaking in 2020?
We all got used to the partnering conference circuit as a means to introduce the latest developments to potential partners. So now they are all temporarily suspended whilst we overcome the current global health challenge, how do you make sure your opportunities are still getting in front of your potential partners. PharmaVentures has been successfully connecting buyers and sellers for over 28 years with and without partnering conferences. PharmaVentures’ CEO, Dr. Fintan Walton talks about how PharmaVentures is continuing a business as usual approach for all of our clients.
In this special edition of PharmaVentures Insights, we explore the challenges faced by pharmaceutical companies during the manufacturing divestment process, and how to accelerate the divestment process to achieve a successful outcome.
Paul Larsmon spoke with leading experts including:
Mark Bamforth, President and CEO, Arranta Bio
Stéphane Lepeu, Directeur Général Délégué / Chief Commercial Officer, DELPHARM
The Chief Executive of PharmaVentures, a leading global corporate advisory firm in healthcare licensing, M&A and fundraising discusses how the current pandemic of 2020 will define the winners and losers in biopharmaceuticals.
What are the most important things to think about when doing a licensing deal with Western big pharma? How do you engage with them and keep the momentum going? Can language become a barrier in doing a deal? How is the Korean biopharmaceutical sector viewed by those of the West? Join Adrian Dawkes, Managing Director and Summer Park, Business Development Director for an exclusive discussion on doing deals with big pharma.
Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea. Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many more innovative technologies and products have emerged. Viewed as the next semi-conductor industry, and therefore a significant boost to the economy and a generator of large numbers of high value jobs, higher numbers of Korean companies and investors have become very active in new drug and technology development – with significant support from the Korean government.
Join Adrian Dawkes and Summer Park of PharmaVentures as they discuss this emerging market and how you can explore the new business opportunities that Korea has to offer.